49P Ramucirumab beyond progression plus TAS 102 in patients with advanced or metastatic adenocarcinoma of the stomach or the gastroesophageal junction, after treatment failure on a ramucirumab based therapy: Final results of the phase II RE-ExPEL study

T.O Goetze,A Stein,S Lorenzen,T Habibzade,E Goekkurt,P Herhaus,D Sookthai,K Ihrig,C Pauligk,S-E Al-Batran

doi:10.1016/j.annonc.2022.10.081

49P Ramucirumab beyond progression plus TAS 102 in patients with advanced or metastatic adenocarcinoma of the stomach or the gastroesophageal junction, after treatment failure on a ramucirumab based therapy: Final results of the phase II RE-ExPEL study

T.O Goetze, A Stein + Show 8 more

https://doi.org/10.1016/j.annonc.2022.10.081

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Publication Date: Nov 1, 2022

Affiliation: Krankenhaus Nordwest, University Cancer Center Hamburg

#Advanced Esophagogastric Adenocarcinoma #Esophagogastric Adenocarcinoma + Show 7 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Based on results of prior trials (TAGS, REGARD, RAINBOW), it seems promising to combine ramucirumab (Ram) beyond progression (PD) with TAS-102 (trifluridine/tipiracil). The purpose of RE-ExPEL is to investigate the tolerability, safety and benefit of Ram beyond PD in combination with TAS-102 in advanced esophagogastric adenocarcinoma (EGA).

Full Text